AlphaQuest LLC Purchases 14,013 Shares of ResMed Inc. $RMD

AlphaQuest LLC boosted its position in ResMed Inc. (NYSE:RMD) by 1,038.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,363 shares of the medical equipment provider’s stock after buying an additional 14,013 shares during the quarter. AlphaQuest LLC’s holdings in ResMed were worth $4,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of ResMed by 1.4% in the 2nd quarter. Vanguard Group Inc. now owns 18,746,925 shares of the medical equipment provider’s stock valued at $4,836,707,000 after purchasing an additional 253,223 shares in the last quarter. State Street Corp raised its position in ResMed by 1.0% in the 2nd quarter. State Street Corp now owns 6,615,852 shares of the medical equipment provider’s stock worth $1,706,890,000 after purchasing an additional 64,448 shares during the period. Geode Capital Management LLC lifted its stake in ResMed by 2.4% in the second quarter. Geode Capital Management LLC now owns 4,215,145 shares of the medical equipment provider’s stock worth $1,083,409,000 after purchasing an additional 98,717 shares during the last quarter. Norges Bank bought a new stake in ResMed in the second quarter worth $306,452,000. Finally, Charles Schwab Investment Management Inc. boosted its position in ResMed by 2.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,021,001 shares of the medical equipment provider’s stock valued at $263,418,000 after buying an additional 22,873 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on RMD. Mizuho decreased their price objective on ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Robert W. Baird restated a “neutral” rating and set a $275.00 price target (down from $300.00) on shares of ResMed in a research report on Tuesday, December 16th. KeyCorp lifted their price target on ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Stifel Nicolaus dropped their price objective on ResMed from $270.00 to $260.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Finally, Wells Fargo & Company assumed coverage on shares of ResMed in a report on Monday, October 13th. They issued an “equal weight” rating and a $280.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $296.09.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — EPS (non‑GAAP $2.81) topped estimates and revenue of $1.423B was ~11% year‑over‑year growth, driven by device and mask demand; investors are pricing in continued top‑line momentum. ResMed beats quarterly profit estimates on strong demand for its sleep devices
• Positive Sentiment: Margins and cash flow improved — GAAP gross margin rose ~320 bps to 61.8%, operating cash flow was ~$340M and non‑GAAP EPS grew mid‑teens, supporting profitability outlook. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Shareholder returns raised — board declared a $0.60 quarterly cash dividend (payable March 19) and the company repurchased $175M of stock in the quarter, boosting capital return credibility. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Product & regulatory progress — received FDA clearance for an AI‑enabled comfort feature (Smart Comfort) that may aid adherence and product differentiation, but commercial impact will be gradual. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Neutral Sentiment: Investor sentiment / analyst context — multiple analysts maintain positive views and price targets remain well above current levels (median ~ $300), which supports upside but also sets expectations. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026
• Negative Sentiment: Costs and one‑time items rose — SG&A and R&D grew (~12% yo‑y on a constant currency basis) and the company recorded ~$6M of restructuring charges; rising operating expenses could cap margin upside if growth slows. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Negative Sentiment: Insider selling activity noted — recent disclosures show multiple insider sales across senior executives over the past 6 months, which some investors view as a cautionary signal. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026

Insider Activity

In related news, Director Witte Jan De sold 2,055 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total transaction of $524,025.00. Following the transaction, the director owned 4,261 shares in the company, valued at $1,086,555. The trade was a 32.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $248.46, for a total transaction of $1,240,063.86. Following the completion of the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $115,837,766.58. The trade was a 1.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 21,594 shares of company stock valued at $5,403,495. Corporate insiders own 0.65% of the company’s stock.

ResMed Price Performance

Shares of RMD stock opened at $257.83 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The firm has a market cap of $37.63 billion, a P/E ratio of 26.39, a P/E/G ratio of 1.73 and a beta of 0.88. The business’s 50 day moving average price is $250.90 and its 200-day moving average price is $263.20.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The company had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.40 billion. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The firm’s revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.43 earnings per share. On average, equities research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.